The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
TIGIT and PD-1 impair tumor antigen–specific CD8+ T cells in melanoma patients
Open accessAbstract
T cell Ig and ITIM domain (TIGIT) is an inhibitory receptor expressed by activated T cells, Tregs, and NK cells. Here, we determined that TIGIT is upregulated on tumor antigen-specific (TA-specific) CD8⁺ T cells and CD8⁺ tumor-infiltrating lymphocytes (TILs) from patients with melanoma, and these TIGIT-expressing CD8⁺ T cells often coexpress the inhibitory receptor PD-1. Moreover, CD8⁺ TILs from patients exhibited downregulation of the costimulatory molecule CD226, which competes with TIGIT for the same ligand, supporting a TIGIT/CD226 imbalance in metastatic melanoma. TIGIT marked early T cell activation and was further upregulated by T cells upon PD-1 blockade and in dysfunctional PD-1⁺TIM-3⁺ TA-specific CD8⁺ T cells. PD-1⁺TIGIT⁺, PD-1⁻TIGIT⁺, and PD-1⁺TIGIT⁻ CD8⁺ TILs had similar functional capacities ex vivo, suggesting that TIGIT alone, or together with PD-1, is not indicative of T cell dysfunction. However, in the presence of TIGIT ligand-expressing cells, TIGIT and PD-1 blockade additively increased proliferation, cytokine production, and degranulation of both TA-specific CD8⁺ T cells and CD8⁺ TILs. Collectively, our results show that TIGIT and PD-1 regulate the expansion and function of TA-specific CD8⁺ T cells and CD8⁺ TILs in melanoma patients and suggest that dual TIGIT and PD-1 blockade should be further explored to elicit potent antitumor CD8⁺ T cell responses in patients with advanced melanoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Self-citationWherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062 · cited 1×
“There is now ample evidence that tumor antigen–specific (TA-specific) CD8 + T cells become dysfunctional and exhausted upon chronic antigen exposure, losing their capacity to proliferate, produce cytokines, and lyse tumor cells (2, 3).”
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986
The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity
Stanietsky, N., Simic, H., Arapovic, J., Toporik, A., Levy, O., Novik, A., Levine, Z., Beiman, M., Dassa, L., Achdout, H., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903474106 · Cited by 3,524
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Self-citationTopalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072
Blackburn, S. D., Shin, H., Haining, W. N., Zou, T., Workman, C. J., Polley, A., Betts, M. R., Freeman, G. J., Vignali, D. A. A., & Wherry, E. J. (2009) · Nature Immunology · doi:10.1038/ni.1679 · Cited by 2,062
Ahmadzadeh, M., Johnson, L. A., Heemskerk, B., Wunderlich, J. R., Dudley, M. E., White, D. E., & Rosenberg, S. A. (2009) · Blood · doi:10.1182/blood-2008-12-195792 · Cited by 1,766
Yu, X., Harden, K., C Gonzalez, L., Francesco, M., Chiang, E., Irving, B., Tom, I., Ivelja, S., Refino, C. J., Clark, H., et al. (2009) · Nature Immunology · doi:10.1038/ni.1674 · Cited by 1,491
Fourcade, J., Sun, Z., Benallaoua, M., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M., Kuchroo, V., & Zarour, H. M. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100637 · Cited by 1,307
Self-citationThe Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function
Johnston, R. J., Comps-Agrar, L., Hackney, J., Yu, X., Huseni, M., Yang, Y., Park, S., Javinal, V., Chiu, H., Irving, B., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.018 · Cited by 1,194
Mendelsohn, C. L., Wimmer, E., & Racaniello, V. R. (1989) · Cell · doi:10.1016/0092-8674(89)90690-9 · Cited by 1,111
Joller, N., Lozano, E., Burkett, P. R., Patel, B., Xiao, S., Zhu, C., Xia, J., Tan, T. G., Sefik, E., Yajnik, V., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.02.012 · Cited by 955
Bottino, C., Castriconi, R., Pende, D., Rivera, P., Nanni, M., Carnemolla, B., Cantoni, C., Grassi, J., Marcenaro, S., Reymond, N., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030788 · Cited by 875
HUMAN T CELL RESPONSES AGAINST MELANOMA
Boon, T., Coulie, P. G., Eynde, B. J. V. D., & Bruggen, P. V. D. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090733 · Cited by 651
DNAM-1, A Novel Adhesion Molecule Involved in the Cytolytic Function of T Lymphocytes
Shibuya, A., Campbell, D., Hannum, C., Yssel, H., Franz-Bacon, K., McClanahan, T., Kitamura, T., Nicholl, J., Sutherland, G. R., Lanier, L. L., et al. (1996) · Immunity · doi:10.1016/s1074-7613(00)70060-4 · Cited by 641
Cutting Edge: TIGIT Has T Cell-Intrinsic Inhibitory Functions
Joller, N., Hafler, J. P., Brynedal, B., Kassam, N., Spoerl, S., Levin, S. D., Sharpe, A. H., & Kuchroo, V. K. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003081 · Cited by 581
Antigen-independent memory CD8 T cells do not develop during chronic viral infection
Wherry, E. J., Barber, D. L., Kaech, S. M., Blattman, J. N., & Ahmed, R. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407192101 · Cited by 497
The TIGIT/CD226 Axis Regulates Human T Cell Function
Lozano, E., Dominguez-Villar, M., Kuchroo, V., & Hafler, D. A. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103627 · Cited by 476
Antigen-specific human antibodies from mice comprising four distinct genetic modifications
Lonberg, N., Taylor, L. D., Harding, F. A., Trounstine, M., Higgins, K. M., Schramm, S. R., Kuo, C.-C., Mashayekh, R., Wymore, K., McCabe, J. G., et al. (1994) · Nature · doi:10.1038/368856a0 · Cited by 398
Fourcade, J., Sun, Z., Pagliano, O., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M., Olive, D., Kuchroo, V., & Zarour, H. M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2637 · Cited by 372
Self-citationFuchs, A., Cella, M., Giurisato, E., Shaw, A. S., & Colonna, M. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.7.3994 · Cited by 358
Vstm3 is a member of the CD28 family and an important modulator of T‐cell function
Levin, S. D., Taft, D. W., Brandt, C. S., Bucher, C., Howard, E. D., Chadwick, E. M., Johnston, J., Hammond, A., Bontadelli, K., Ardourel, D., et al. (2011) · European Journal of Immunology · doi:10.1002/eji.201041136 · Cited by 356
Tahara-Hanaoka, S. (2004) · International Immunology · doi:10.1093/intimm/dxh059 · Cited by 286
DNAM-1 and PVR Regulate Monocyte Migration through Endothelial Junctions
Reymond, N., Imbert, A.-M., Devilard, E., Fabre, S., Chabannon, C., Xerri, L., Farnarier, C., Cantoni, C., Bottino, C., Moretta, A., et al. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20032206 · Cited by 279
A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC
Boles, K. S., Vermi, W., Facchetti, F., Fuchs, A., Wilson, T. J., Diacovo, T. G., Cella, M., & Colonna, M. (2009) · European Journal of Immunology · doi:10.1002/eji.200839116 · Cited by 268
Pende, D., Castriconi, R., Romagnani, P., Spaggiari, G. M., Marcenaro, S., Dondero, A., Lazzeri, E., Lasagni, L., Martini, S., Rivera, P., et al. (2006) · Blood · doi:10.1182/blood-2005-07-2696 · Cited by 268
High-avidity human IgGκ monoclonal antibodies from a novel strain of minilocus transgenic mice
Fishwild, D. M., O'Donnell, S. L., Bengoechea, T., Hudson, D. V., Harding, F., Bernhard, S. L., Jones, D., Kay, R. M., Higgins, K. M., Schramm, S. R., et al. (1996) · Nature Biotechnology · doi:10.1038/nbt0796-845 · Cited by 266
Shibuya, K., Shirakawa, J., Kameyama, T., Honda, S.-I., Tahara-Hanaoka, S., Miyamoto, A., Onodera, M., Sumida, T., Nakauchi, H., Miyoshi, H., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030958 · Cited by 250
CD155/PVR plays a key role in cell motility during tumor cell invasion and migration
Sloan, K. E., Eustace, B. K., Stewart, J. K., Zehetmeier, C., Torella, C., Simeone, M., Roy, J. E., Unger, C., Louis, D. N., Ilag, L. L., et al. (2004) · BMC Cancer · doi:10.1186/1471-2407-4-73 · Cited by 244
Stengel, K. F., Harden-Bowles, K., Yu, X., Rouge, L., Yin, J., Comps-Agrar, L., Wiesmann, C., Bazan, J. F., Eaton, D. L., & Grogan, J. L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1120606109 · Cited by 217
Fourcade, J., Sun, Z., Pagliano, O., Chauvin, J.-M., Sander, C., Janjic, B., Tarhini, A. A., Tawbi, H. A., Kirkwood, J. M., Moschos, S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2908 · Cited by 209
Self-citationLopez, M., Aoubala, M., Jordier, F., Isnardon, D., Gomez, S., & Dubreuil, P. (1998) · Blood · doi:10.1182/blood.v92.12.4602 · Cited by 166
Ardolino, M., Zingoni, A., Cerboni, C., Cecere, F., Soriani, A., Iannitto, M. L., & Santoni, A. (2011) · Blood · doi:10.1182/blood-2010-08-300954 · Cited by 162
PD-1 Is a Regulator of NY-ESO-1-Specific CD8+ T Cell Expansion in Melanoma Patients
Fourcade, J., Kudela, P., Sun, Z., Shen, H., Land, S. R., Lenzner, D., Guillaume, P., Luescher, I. F., Sander, C., Ferrone, S., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803245 · Cited by 161
Self-citationCasado, J. G., Pawelec, G., Morgado, S., Sánchez-Correa, B., Delgado, E., Gayoso, I., Durán, E., Solana, R., & Tarazona, R. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-009-0682-y · Cited by 148
Zhang, Y., Maksimovic, J., Naselli, G., Qian, J., Chopin, M., Blewitt, M. E., Oshlack, A., & Harrison, L. C. (2013) · Blood · doi:10.1182/blood-2013-02-481788 · Cited by 147
Nectin like-5 overexpression correlates with the malignant phenotype in cutaneous melanoma
Bevelacqua, V., Bevelacqua, Y., Candido, S., Skarmoutsou, E., Amoroso, A., Guarneri, C., Strazzanti, A., Gangemi, P., Mazzarino, M. C., D’Amico, F., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.594 · Cited by 114
Nectin-2 is a potential target for antibody therapy of breast and ovarian cancers
Oshima, T., Sato, S., Kato, J., Ito, Y., Watanabe, T., Tsuji, I., Hori, A., Kurokawa, T., & Kokubo, T. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-60 · Cited by 109
Kamran, N., Takai, Y., Miyoshi, J., Biswas, S. K., Wong, J. S. B., & Gasser, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054406 · Cited by 92
Poliovirus Receptor on Human Blood Cells: A Possible Extraneural Site of Poliovirus Replication
Freistadt, M. S., Fleit, H. B., & Wimmer, E. (1993) · Virology · doi:10.1006/viro.1993.1433 · Cited by 70
Bidirectional entry of poliovirus into polarized epithelial cells
Tucker, S. P., Thornton, C. L., Wimmer, E., & Compans, R. W. (1993) · Journal of Virology · doi:10.1128/jvi.67.1.29-38.1993 · Cited by 27
Cited by
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Waldman, A. D., Fritz, J. M., & Lenardo, M. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0306-5 · Cited by 4,154
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088
Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,400
Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation
Anderson, A. C., Joller, N., & Kuchroo, V. K. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.001 · Cited by 2,096
CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer
McLane, L. M., Abdel-Hakeem, M. S., & Wherry, E. J. (2019) · Annual Review of Immunology · doi:10.1146/annurev-immunol-041015-055318 · Cited by 1,975
Metadata
- Authors
- Chauvin, J.-M., Pagliano, O., Fourcade, J., Sun, Z., Wang, H., Sander, C., Kirkwood, J. M., Chen, T.-H. T., Maurer, M., Korman, A. J., & Zarour, H. M.
- Venue
- Journal of Clinical Investigation
- Published
- 2015-04-13
- Volume
- 125
- Issue
- 5
- Pages
- 2046-2058
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W1987165863
- Cited by
- 784
- References
- 45
- FWCI
- 20.67
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.